{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-092520","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.978204+00:00","generated_at":"2026-06-04T00:07:45.616204+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eliem to acquire Tenet Medicines in stock deal; raises $120M PIPE at $3.84/share","bullets":["Eliem (ELYM) acquires Tenet via merger; Tenet holders get 15.4% of combined co. stock.","PIPE raises $120M from accredited investors at $3.84/share; closes after merger.","Stephen Thomas (Tenet CEO) to become interim CEO; William Bonificio interim CBO.","Combined board expands to 7 members: 5 current Eliem directors, Thomas, and 1 Tenet designee.","Deal requires disinterested stockholder vote; termination fee of $1M payable under certain conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-092520","json":"https://secwatch.observer/filing/0001193125-24-092520.json","markdown":"https://secwatch.observer/filing/0001193125-24-092520.md","text":"https://secwatch.observer/filing/0001193125-24-092520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312524092520/0001193125-24-092520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312524092520/d737147d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:07:45.616204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06bb239e645d91f84ab9013b8c8e66c6dc6a2c87","claim":"Climb Bio, Inc. entered into Securities Purchase Agreement with several accredited institutional investors valued at 31,238,282 shares of the Company’s common stock ... at a price of $3.84 per PIPE Share (effective 2024-04-10).","evidence_excerpt":"On April 10, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with several accredited institutional investors (the “PIPE Investors”), pursuant to which the Company agreed to issue and sell to the PIPE Investors in a private placement an aggregate of 31,238,282 shares of the Company’s common stock (the “PIPE Shares”), at a price of $3.84 per PIPE Share (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312524092520/0001193125-24-092520-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"several accredited institutional investors"},{"label":"Value","value":"31,238,282 shares of the Company’s common stock ... at a price of $3.84 per PIPE Share"},{"label":"Effective","value":"2024-04-10"}],"fact_type":"material_agreement"},{"claim_id":"5fe1bec7d5f0d290017115e616c0aa6469e77394","claim":"Climb Bio, Inc. entered into Agreement and Plan of Merger and Reorganization with Tenet Medicines, Inc. (effective 2024-04-10).","evidence_excerpt":"On April 10, 2024, Eliem Therapeutics, Inc. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization (the “Acquisition Agreement”) by and among the Company, Tango Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Transitory Subsidiary”), Tenet Medicines, Inc., a Delaware corporation (“Tenet”), and, solely in his capacity as company equityholder representative, Stephen Thomas.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312524092520/0001193125-24-092520-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Tenet Medicines, Inc."},{"label":"Effective","value":"2024-04-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}